SCHEMBL4896573

SCHEMBL4896573

COc1cc(C23CC4CC(CC(C4)C2)C3)c(O)c(S(=O)(=O)Nc2ccc(C#N)cc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 4/20 0.49
ALPL P05186 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
MCL1 Q07820 2/20 0.41
BRD4 O60885 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
GAA P10253 2/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.37
KDM1A O60341 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
BCL2L1 Q07817 1/20 0.37
PI4KB Q9UBF8 1/20 0.37
SLC22A12 Q96S37 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4884915 0.87 PGR (0.52) PGRMCL1BRD4SMN1; SMN2GAA
SCHEMBL4886499 0.86 ACLY (0.44) PGRALDH1A1SLC22A12
SCHEMBL4895380 0.85 PGR (0.49) PGRMAPTMCL1BRD4KDM1A
SCHEMBL4886491 0.73 SLC22A12 (0.45) PGRTSHRSLC22A12
SCHEMBL4897237 0.71 SLC22A12 (0.45) PGRSLC22A12
SCHEMBL12368216 0.70 ALPL (0.72) ALPLLMNASMN1; SMN2POLBMEN1
SCHEMBL4896085 0.66 SLC22A12 (0.50) LMNAMAPTMCL1BRD4KDM1A
SCHEMBL7276225 0.66 PKM (0.68) PGRLMNAMAPTSMN1; SMN2GAA
SCHEMBL6447663 0.65 CNR2 (0.50) PGRLMNAMAPTMCL1SMN1; SMN2
SCHEMBL6448167 0.65 ERN1 (0.42) PGRLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US claimed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP claimed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO claimed
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS PGR 4193/4885ALPL 4171/4885LMNA 4327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.